{"filing":{"accession_number":"0001213900-26-083987","cik":"0001875091","ticker":"NRSNW","company_name":"NeuroSense Therapeutics Ltd.","form":"6-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"ea0299821-6k_neuro.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026083987/ea0299821-6k_neuro.htm"},"events":[{"id":22409,"run_id":20272,"accession_number":"0001213900-26-083987","anchor_item_number":"EX-99.1","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"This is a notice and proxy statement for a special shareholder meeting scheduled for August 26, 2026, calling shareholders to vote on a reverse share split proposal (1-for-4 to 1-for-40 ratio). While the exhibit is technically a notice/proxy solicitation rather than a report of voting results, it discloses a material shareholder vote on a proposal directly tied to Nasdaq delisting risk—the Company received Listing Qualification Notices on April 2, 2026, for failure to maintain minimum bid price ($1.00) and market value ($35 million) requirements, with a compliance deadline of September 29, 2026. The reverse split is explicitly intended to raise share price to avoid delisting. This is material to investors because delisting would impair liquidity and financing ability. The shareholder vote on this proposal is the substantive disclosure event.","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-07-31","form":"6-K","submitted_at":null,"items":[{"id":22338,"accession_number":"0001213900-26-083987","item_number":"EX-99.1","item_title":"ea029982101ex99-1.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This is a notice and proxy statement for a special shareholder meeting scheduled for August 26, 2026, calling shareholders to vote on a reverse share split proposal (1-for-4 to 1-for-40 ratio). While the exhibit is technically a notice/proxy solicitation rather than a report of voting results, it discloses a material shareholder vote on a proposal directly tied to Nasdaq delisting risk—the Company received Listing Qualification Notices on April 2, 2026, for failure to maintain minimum bid price ($1.00) and market value ($35 million) requirements, with a compliance deadline of September 29, 2026. The reverse split is explicitly intended to raise share price to avoid delisting. This is material to investors because delisting would impair liquidity and financing ability. The shareholder vote on this proposal is the substantive disclosure event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:14:10.286315+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22338,"accession_number":"0001213900-26-083987","item_number":"EX-99.1","item_title":"ea029982101ex99-1.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This is a notice and proxy statement for a special shareholder meeting scheduled for August 26, 2026, calling shareholders to vote on a reverse share split proposal (1-for-4 to 1-for-40 ratio). While the exhibit is technically a notice/proxy solicitation rather than a report of voting results, it discloses a material shareholder vote on a proposal directly tied to Nasdaq delisting risk—the Company received Listing Qualification Notices on April 2, 2026, for failure to maintain minimum bid price ($1.00) and market value ($35 million) requirements, with a compliance deadline of September 29, 2026. The reverse split is explicitly intended to raise share price to avoid delisting. This is material to investors because delisting would impair liquidity and financing ability. The shareholder vote on this proposal is the substantive disclosure event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:14:10.286315+00:00","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-07-31"}]}